AstraZeneca’s new weight-loss pill, AZD5004, shows promise in early trials with tolerable side effects, advancing to Phase II studies focused on reducing obesity.
AstraZeneca reported on Monday that its experimental weight-loss pill, AZD5004, licensed from China's Eccogene for up to $2 billion, was found safe and tolerable in an early-stage trial.
The study, which included 72 participants who were either healthy or had type 2 diabetes, showed side effects consistent with other GLP-1 drugs, such as nausea and vomiting. Based on these findings, AstraZeneca has advanced AZD5004 to Phase II trials focused on weight reduction in overweight and obese individuals, with completion expected by late 2025.
Unlike injectable treatments from competitors Eli Lilly and Novo Nordisk, AZD5004 is a small molecule pill that can be combined with other medications and taken with or without food, offering potential advantages for patients with additional health conditions.
AstraZeneca also shared early-stage data on other obesity drugs, AZD6234 and AZD9550, which target different hunger-related hormones and will undergo further Phase II testing through 2026.
Meanwhile, Viking Therapeutics released early trial results for its own oral obesity drug, which briefly boosted its stock before a decline.
Start your day informed with AnewZ Morning Brief: here are the top news stories for the 10th of December, covering the latest developments you need to...
The world’s leading minds and voices will be honoured on Wednesday, 10 December, the anniversary of Alfred Nobel’s death, as Nobel Prizes are pres...
The United Nations Security Council has issued warnings about the rapidly worsening humanitarian crisis in Ukraine, citing a sharp surge in civilian c...
Ukrainian President Volodymyr Zelenskyy said on Tuesday he was prepared to hold elections within three months if the U.S. and Kyiv's other allies coul...
Fighting between Thailand and Cambodia entered into a third day on Wednesday as U.S. President Donald Trump said he would make a phone call to stop th...
A groundbreaking study presented at ASCO reveals that AstraZeneca’s experimental pill camizestrant, when used based on blood test results, can halve the risk of breast cancer progression or death—potentially reshaping treatment for patients with hormone receptor-positive, HER2-negative breast cancer
AstraZeneca, opens new tab said it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year.
Authorities in Japan lifted all tsunami warnings on Tuesday following a strong 7.5-magnitude earthquake that struck off the northeastern coast late on Monday, injuring at least 30 people and forcing around 90,000 residents to evacuate their homes.
Scores of demonstrators gathered outside the Norwegian Nobel Institute in Oslo Tuesday (9 December) to protest against the awarding of this year’s Nobel Peace Prize to Venezuelan opposition leader Maria Corina Machado.
Pressure is mounting between Venezuela and the United States as both nations emphasise military preparedness and strategic positioning.
Tehran has protested to Washington because of the travel ban on its football team delegation as well as Iranian fans who would like to travel to the United States for the upcoming World Cup matches in 2026.
Paramount Skydance (PSKY.O) has launched a $108.4 billion hostile takeover bid for Warner Bros Discovery (WBD.O). The escalation follows a high-stakes battle that had appeared to end last week when Netflix secured a $72 billion deal for the studio giant’s assets.
A viral claim circulating online that Denmark requires sperm donors to have an IQ of at least 85 is misleading. While one Danish sperm bank, Donor Network, does use an IQ threshold, there is no nationwide legal requirement for donors to meet a specific level of intelligence.
Chinese scientists have unveiled a new gene-editing therapy that they say could lead to a functional cure for HIV, making it one of the most promising developments in decades of global research.
The Democratic Republic of the Congo (DRC) has declared the end of a 16th Ebola outbreak, closing a two month emergency in Kasai Province that pushed national and international teams into an intensive response.
The U.S. Food and Drug Administration Commissioner Marty Makary said on Saturday that data showed 10 children had died because of COVID-19 vaccination shots.
The Spanish agricultural sector has been placed on high alert following the confirmation that African Swine Fever (ASF) has resurfaced in the country for the first time in over thirty years.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment